Jerry is formerly CEO of Kew Inc., which provides comprehensive genomic testing services that enable oncologists to make evidence-driven personalized treatment decisions for cancer patients. Performance-driven, entrepreneur with thirty years of progressive experience in bioscience markets for life science research, diagnostics/devices and analytical products. Including former CEO of Metamark Genetics, Genetix, Biacore, and Pyrosequencing. Successful track record of establishing/leading profitable businesses; recruiting and developing top-performing global commercial organizations; creating substantial shareholder value through business development/licensing/strategic partnerships; raising capital; and managing successful exits.
David has been responsible for commercializing the NanoView technology from concept to fundraising to product development. Post investment, David has established an experienced team of experts to deliver the NanoView technology to market.
‘I’m really excited by the team we have put together at NanoView Biosciences. Our investor Directors add a wealth of industry knowledge and our internal team has years of experience in developing novel technologies and bringing them to market. Our goal at NanoView Biosciences, is to deliver a disruptive technology to the extracellular vesicle market and beyond. Our product answers questions that can’t be solved by other means and we are looking forward to developing strategic partnerships with academia and industry alike, to ensure that our technology meets current and future needs. We fully expect that our technology will change the face of research within the extracellular vesicle community as well as form the basis of future diagnostics based on EV biomarkers.'
David's goal is to help save lives by creating better life science and diagnostic tools that have a clear market need. David was educated at UCSD in Electronics and Economics before moving to Boston University to complete his PhD and PostDoc in Electrical Engineering.
President & CSO
George co-invented the Single Particle Interferometric Reflectance Imaging Sensor (IRIS) in Dr. Ünlü’s lab, which is the fundamental technology on which the ExoView platform is based on. George’s graduate work focused on the development of biosensors for digital detection and counting of viral pathogens and cancer biomarkers. George has published numerous papers on the sensitive, multiplexed detection of viral hemorrhagic fever viruses (Ebola and Marburg) from serum and whole blood. As a full-time CSO at NanoView Diagnostics Inc., George leads the assay development and validation of the ExoView cartridge.
VP of Sales & Marketing
Andrew has more than 10 years of experience in instrumentation covering NTA, DLS and super-resolution techniques. Andrew was one of the early pioneers in introducing and developing the NTA technique within the exosome community.
“It is clear that the tools that EV researchers have at their disposal, result in gaps in their analytical capabilities especially as the requirements of the community have developed at an exponential rate in recent years. I am really excited to be working with the ExoView platform, it answers many of the questions that researchers are looking for answers for. The fact that it works without purification and provides phenotyping, quantification and sizing really excites me and I fully expect the technology to go beyond a research tool, to eventually be used in a clinical/diagnostic capacity in the future. The team at NanoView is really fantastic too, it’s like a family here and everyone is working hard to do great science as well as look after our most valuable resource which is our customer interactions.”
Ian was the Chairman and CEO of Enzymatics, a leading producer of reagents, kits, and assays that enable customers worldwide to transform patient diagnosis, treatment, and life science research. Ian was a founder, CEO and a director of Stemgent Inc. Stemgent Inc. is a life science company focused on the development and sale of novel consumable reagents, and a leading global provider of high quality, human tissue and human tissue-based research solutions to drug discovery scientists. Prior to Stemgent, he served as President of Upstate, a leading provider of cell signaling research products and services. In this position Ian was instrumental in facilitating the acquisition of Upstate by Serologicals, Corp. and was subsequently retained as President of the Upstate division. Ian earned a degree in Chemical Engineering from University of Surrey and has an MBA from the Darden Graduate School of Business Administration at the University of Virginia. He is a director of Global Cell Solutions LLC (Charlottesville), a biotech company commercializing proprietary 3D cell culture technology.
Parker has spent over a decade as an entrepreneurial general manager with leadership experience in diagnostics, medical devices, and research tools at Becton Dickinson and Millipore. Parker’s expertise extends to profit and loss management, new product development, strategy development, mergers and acquisitions/integration, and new team formation. Parker was recently an Entrepreneur in Residence at RA Capital Management and is currently Chief Commercial Officer at Mitra Biotech, a cancer diagnostic company.